Expense Accounting in the Wake of Enron
As Elan Pharmaceuticals' problems with the SEC bring home to the drug industry, companies can expect P&L-sparing strategies to come under increasing scrutiny. The practices likely to be affected include: capitalizing deal-related payments such as milestones and royalties; pharma investments in biotech equity; and joint venture arrangements.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.